SVB Leerink Maintains Outperform on Mersana Therapeutics, Raises Price Target to $14
SVB Leerink analyst Jonathan Chang maintains Mersana Therapeutics (NASDAQ:MRSN) with a Outperform and raises the price target from $13 to $14.
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell
• Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
34 Stocks Moving In Monday’s Mid-Day Session
Gainers
Casa Systems, Inc. (NASDAQ: CASA) shares climbed 66.3% to $6.47 after the company announced a multi-year contract with Verizon to provide 5G core network functions.
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron’s COVID-19 Therapy Decision Pushed, Protagonist’s Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Recap: Mersana Therapeutics Q4 Earnings
Mersana Therapeutics (NASDAQ:MRSN) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
Mersana Therapeutics Q4 EPS $(0.68) Misses $(0.67) Estimate
Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.67) by 1.49 percent. This is a 61.9 percent decrease over losses of $(0.42) per share
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
